IXC 10.5% 6.0¢ invex therapeutics ltd

"The Company has filed an additional ODD for the US Market for...

  1. 941 Posts.
    lightbulb Created with Sketch. 302
    "The Company has filed an additional ODD for the US Market for moderate to severe TBI, which if
    granted in 2H CY2023 will provide seven years market exclusivity for Exenatide, certain tax credits
    and a waiver from the Prescription Drug User Fee Act (PDUFA) fees, which were approximately
    US$3.1 million in 2022. A proof of concept clinical trial for Exenatide to lower ICP in moderate to
    severe TBI is under consideration."

    This seems to be the key part from the 4C comments.
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
(20min delay)
Last
6.0¢
Change
-0.007(10.5%)
Mkt cap ! $4.509M
Open High Low Value Volume
6.0¢ 6.0¢ 6.0¢ $3.264K 54.4K

Buyers (Bids)

No. Vol. Price($)
1 600 6.0¢
 

Sellers (Offers)

Price($) Vol. No.
7.0¢ 20000 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.